Study Summary
This trial is testing a new cancer treatment that uses modified immune cells to target and kill ovarian cancer cells.
- Stage IVB Primary Peritoneal Cancer
- Stage IIIB Primary Peritoneal Cancer
- Stage IIIC Fallopian Tube Cancer
- Platinum-Resistant Fallopian Tube Carcinoma
- Refractory Fallopian Tube Carcinoma
- Stage IIIA Primary Peritoneal Cancer
- Stage III Fallopian Tube Cancer
- Stage III Primary Peritoneal Cancer
- Stage IIIC Primary Peritoneal Cancer
- Stage IV Primary Peritoneal Cancer
- Stage IVA Primary Peritoneal Cancer
- Stage IVA Fallopian Tube Cancer
- Stage IIIB Fallopian Tube Cancer
- Recurrent Fallopian Tube Cancer
- Stage IV Fallopian Tube Cancer
- Stage IIIA1 Fallopian Tube Cancer
- Stage IIIA Fallopian Tube Cancer
- Stage IVA Ovarian Cancer
- Stage IIIA2 Fallopian Tube Cancer
- Refractory Ovarian Cancer
- Platinum-resistant Ovarian Cancer
- Stage III Ovarian Cancer
- Stage IIIA1 Ovarian Cancer
- Stage IV Ovarian Cancer
- Recurrent Primary Peritoneal Carcinoma
- Stage IVB Fallopian Tube Cancer
- Stage IVB Ovarian Cancer
- Platinum-Resistant Primary Peritoneal Carcinoma
- Recurrent Ovarian Cancer
- Refractory Primary Peritoneal Carcinoma
- Stage IIIB Ovarian Cancer
- Stage IIIA2 Ovarian Cancer
- Stage IIIA Ovarian Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
2 Primary · 2 Secondary · Reporting Duration: Up to 5 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Treatment (PRGN-3005 UltraCAR-T cells) IP Administration
1 of 2
Treatment (PRGN-3005 UltraCAR-T cells) IV Administration
1 of 2
Experimental Treatment
71 Total Participants · 2 Treatment Groups
Primary Treatment: PRGN-3005 UltraCAR-T cells · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Female Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is there an open call for participants in this trial?
"Evidenced by the clinicaltrials.gov page, this trial is currently open to participants. The medical experiment was initiated on April 30th 2019 and its details were most recently updated as of June 28th 2022." - Anonymous Online Contributor
What potential adverse effects could arise from the use of PRGN-3005 UltraCAR-T cells?
"The safety of PRGN-3005 UltraCAR-T cells is deemed to be a 1 on the scale, as this phase one trial only has limited data that supports its efficacy and security." - Anonymous Online Contributor
What is the total sample size for this medical trial?
"Affirmative. According to clinicaltrials.gov, the research study went live on April 30th 2019 and was last revised on June 28th 2022. 71 individuals are being recruited from one medical centre for this trial." - Anonymous Online Contributor